AAV2-mediated gene therapy for Bietti crystalline dystrophy provides functional CYP4V2 in multiple relevant cell models
Open Access
- 9 June 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-13
Abstract
Bietti crystalline dystrophy (BCD) is an inherited retinal disease (IRD) caused by mutations in the CYP4V2 gene. It is a relatively common cause of IRD in east Asia. A number of features of this disease make it highly amenable to gene supplementation therapy. This study aims to validate a series of essential precursor in vitro experiments prior to developing a clinical gene therapy for BCD. We demonstrated that HEK293, ARPE19, and patient induced pluripotent stem cell (iPSC)-derived RPE cells transduced with AAV2 vectors encoding codon optimization of CYP4V2 (AAV2.coCYP4V2) resulted in elevated protein expression levels of CYP4V2 compared to those transduced with AAV2 vectors encoding wild type CYP4V2 (AAV2.wtCYP4V2), as assessed by immunocytochemistry and western blot. Similarly, we observed significantly increased CYP4V2 enzyme activity in cells transduced with AAV2.coCYP4V2 compared to those transduced with AAV2.wtCYP4V2. We also showed CYP4V2 expression in human RPE/choroid explants transduced with AAV2.coCYP4V2 compared to those transduced with AAV2.wtCYP4V2. These preclinical data support the further development of a gene supplementation therapy for a currently untreatable blinding condition—BCD. Codon-optimized CYP4V2 transgene was superior to wild type in terms of protein expression and enzyme activity. Ex vivo culture of human RPE cells provided an effective approach to test AAV-mediated transgene delivery.Keywords
Funding Information
- DHB Foundation
- NHMRC Senior Research Fellowship (1153498)
- Hector Maclean Scholarship
- the University of Melbourne Annemarie Mankiewicz-Zelkin Fellowship
This publication has 45 references indexed in Scilit:
- Induced pluripotent stem cells: opportunities and challengesPhilosophical Transactions of the Royal Society B: Biological Sciences, 2011
- Finding Homes for Orphan Cytochrome P450s: CYP4V2 and CYP4F22 in Disease StatesMolecular Interventions, 2011
- A Novel Compound Heterozygous Mutation in the CYP4V2 Gene in a Japanese Patient with Bietti’s Crystalline Corneoretinal DystrophyCase Reports in Ophthalmology, 2011
- Alterations in Serum Fatty Acid Concentrations and Desaturase Activities in Bietti Crystalline Dystrophy Unaffected byCYP4V2GenotypesInvestigative Ophthalmology & Visual Science, 2010
- Expression and Characterization of CYP4V2 as a Fatty Acid ω-HydroxylaseDrug Metabolism and Disposition, 2009
- Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct MinimaJournal of Molecular Biology, 2008
- Induced Pluripotent Stem Cell Lines Derived from Human Somatic CellsScience, 2007
- Bietti Crystalline Corneoretinal Dystrophy Is Caused by Mutations in the Novel Gene CYP4V2The American Journal of Human Genetics, 2004
- HET0016, a potent and selective inhibitor of 20‐HETE synthesizing enzymeBritish Journal of Pharmacology, 2001
- ARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated PropertiesExperimental Eye Research, 1996